WebDoctor Encyclopedia

Soft-tissue sarcomas

Low-grade fibromyxoid sarcoma (LGFMS)

Low-grade fibromyxoid sarcoma (LGFMS) is a rare, slow-growing soft-tissue sarcoma of young and middle-aged adults, usually in the thigh or trunk. It is treated with wide surgery, but it can recur or spread to the lungs many years later.

Medically reviewed Last reviewed October 17, 2026

What is low-grade fibromyxoid sarcoma?

Low-grade fibromyxoid sarcoma (LGFMS) is a rare, slow-growing soft-tissue cancer. It develops from fibroblasts, the cells that make the fibrous framework of connective tissue.

The name describes what the tumour looks like under the microscope: a mixture of fibrous (collagen-rich) and myxoid (soft, gel-like) areas made of cells that look deceptively harmless. It is sometimes called Evans tumour, after the pathologist who first described it in 1987.

LGFMS is very rare. A Danish national study estimated an incidence of about 0.18 cases per million people each year (Maretty-Nielsen et al., 2013). It most often affects young and middle-aged adults, usually in their 20s to 40s, but it can occur in children.

Although it is called “low grade” and grows slowly, LGFMS is a true sarcoma. It can come back after surgery and can spread to the lungs, sometimes many years or even decades after the first operation (Evans, 2011). This is why complete surgery and long-term follow-up are so important.

1. Key facts at a glance

Feature Details
Type of cancer Low-grade fibroblastic soft-tissue sarcoma
How common Very rare; under 1 case per million people per year
Typical age Mostly 20-50 years; children can be affected
Common sites Deep soft tissues of the thigh, shoulder, trunk and groin
Key symptom A slowly enlarging, usually painless lump
Key test Biopsy showing MUC4-positive cells and a FUS::CREB3L2 fusion
Main treatment Wide surgical removal; radiotherapy in selected cases
Special feature Late recurrence and lung spread can occur many years later
Outlook Good survival in the first decade; long-term follow-up needed

2. Causes and genetics

The cause of LGFMS is not known. It is not inherited and is not linked with lifestyle factors.

Most tumours carry a characteristic gene change created when two chromosomes swap pieces, called a translocation.

Gene change How often Notes
FUS::CREB3L2 About 90% Created by t(7;16); highly specific for LGFMS (Panagopoulos et al., 2004)
FUS::CREB3L1 Uncommon Similar behaviour
EWSR1::CREB3L1 Rare More often seen in sclerosing epithelioid fibrosarcoma

These changes are found only in the tumour cells. They are useful for diagnosis but cannot be passed on to children.

Tumour Relationship
Hyalinising spindle cell tumour with giant rosettes A variant of LGFMS with rosette-like collagen structures (Lane, Shannon and Weiss, 1997)
Sclerosing epithelioid fibrosarcoma (SEF) A related, more aggressive sarcoma; hybrid LGFMS-SEF tumours exist

3. How does it look

On the body

Feature Description
Lump Firm, rubbery, usually painless and slowly growing
Depth Usually deep, below the fascia (the tough layer covering muscles)
Size Often 5-10 cm by the time it is found, because it grows slowly
Skin Normal over the lump
Location Thigh, buttock, shoulder, chest wall, armpit, groin; occasionally the abdomen or head and neck

On scans

MRI usually shows a well-defined mass in the deep soft tissues. Fibrous areas look dark and myxoid areas look bright on some sequences, giving a mixed or layered appearance. A CT of the chest looks for spread to the lungs.

Under the microscope

Feature Description
Cells Bland, spindle-shaped cells with little variation in shape
Pattern Alternating fibrous and myxoid zones; swirling (whorled) arrangement
Blood vessels Arcades of small curving vessels in the myxoid areas
Collagen rosettes Present in some tumours
Key stain MUC4 positive in almost all cases (Doyle et al., 2011)
Dividing cells Few; necrosis is unusual

Because the cells look so harmless, LGFMS was often mistaken for a benign tumour in the past. Diagnosis by an expert sarcoma pathologist is recommended.

4. Symptoms

Common symptoms

  • A lump deep in the thigh, shoulder, trunk or groin
  • Gradual growth over months or years
  • Usually no pain, although a large lump may ache
  • Discomfort or stiffness if the lump presses on muscles or joints
  • Numbness or tingling if it presses on a nerve (uncommon)

Symptoms depending on site

Site Possible symptoms
Abdomen or pelvis Tummy fullness, discomfort, changes in bowel or bladder habit
Chest wall A lump or ache in the chest
Head and neck A visible lump; rarely difficulty swallowing

Symptoms of spread

Site Possible symptoms
Lungs Usually none at first; later cough, breathlessness or chest pain
Pleura (lung lining) Fluid around the lung causing breathlessness
Bone or other organs Pain at the site (rare)

When to seek medical advice

See a doctor about any soft-tissue lump that is bigger than about 5 cm, getting bigger, deep in the muscle, or painful. These features need an urgent scan, ideally at a sarcoma centre.

5. Diagnosis

Test Purpose
Ultrasound Often the first test for a lump
MRI Shows the size, depth and relation to nerves, vessels and bone
Core needle biopsy Samples tissue for diagnosis; done at or planned by a sarcoma centre
MUC4 staining Highly sensitive and specific for LGFMS
FISH or sequencing Detects FUS or EWSR1 rearrangements
CT of the chest Looks for lung spread

The biopsy should be planned with the sarcoma surgeon, so that the biopsy track can be removed during the later operation.

Conditions that can look similar

Condition How it differs
Desmoid tumour Beta-catenin positive; does not spread
Myxofibrosarcoma Usually older adults; more variable, atypical cells; MUC4-negative
Neurofibroma or perineurioma Benign nerve-sheath tumours with different stains
Myxoma Benign; GNAS changes in intramuscular myxoma
Sclerosing epithelioid fibrosarcoma Related, more aggressive; epithelioid cells in dense collagen

6. Treatment

People with LGFMS should be treated by a specialist sarcoma team, following guidelines such as those of ESMO (Gronchi et al., 2021).

Surgery

The main treatment is wide local excision: removing the tumour with a margin of healthy tissue all around it.

Situation Approach
Removable tumour Wide excision with clear margins
Incomplete earlier removal (“whoops” excision) Re-excision of the scar area to achieve clear margins
Tumour near nerves or vessels Careful planning to preserve function; sometimes radiotherapy is added
Local recurrence Further surgery whenever possible
Lung metastases Surgical removal of lung nodules in selected patients (Maretty-Nielsen et al., 2013)

Amputation is very rarely needed.

The first operation gives the best chance of cure. When a sarcoma is removed without planning, for example because it was thought to be a harmless lump, cells are often left behind and a second, larger operation is needed. This is why any deep or growing lump should be scanned and, if suspicious, referred to a sarcoma centre before surgery.

Radiotherapy

Radiotherapy may be used before or after surgery when the tumour is large, deep or close to vital structures, or when margins are close. It reduces the risk of the tumour returning locally.

Chemotherapy and other drugs

LGFMS grows slowly and generally responds poorly to chemotherapy. Chemotherapy is not routine but may be considered for widespread disease that is growing and causing symptoms.

Option Notes
Doxorubicin-based chemotherapy Limited responses
Trabectedin, pazopanib Used in some cases of advanced sarcoma
Observation Often appropriate for small, stable lung nodules
Clinical trials Recommended for advanced disease

What treatment involves day to day

Part of treatment What to expect
Before surgery MRI and chest CT, a planned biopsy and a meeting with the sarcoma team
Radiotherapy before surgery (if used) Daily treatments on weekdays for about 5 weeks, then surgery a few weeks later
Surgery Usually a few days in hospital, longer for large or complex operations
Reconstruction Sometimes a skin graft or tissue flap to close the wound
Rehabilitation Physiotherapy to restore movement and strength, often for several months
Return to work Often within weeks to a few months, depending on the site and type of job

Most people with LGFMS are treated with surgery alone and can return to normal activities once the wound has healed.

LGFMS in children and teenagers

LGFMS can occur in children and adolescents. Treatment follows the same principles: complete surgical removal, avoiding radiotherapy where possible because of its effects on growing tissues. Children are usually treated at a children’s sarcoma centre within protocols for non-rhabdomyosarcoma soft-tissue sarcomas.

Side effects

Treatment Possible side effects
Surgery Wound healing problems, scarring, weakness or stiffness; physiotherapy helps recovery
Radiotherapy Skin redness, tiredness, wound problems, long-term stiffness or swelling (lymphoedema)
Chemotherapy Tiredness, hair loss, sickness, infections

7. Outlook (prognosis)

The outlook depends on complete removal and the length of follow-up.

Measure What studies show
Short to medium follow-up (73 patients) Few recurrences or metastases within about 3-4 years (Folpe et al., 2000)
Long-term follow-up (33 patients, median about 14 years) Recurrence in about 64%, metastasis in about 45%, death from disease in about 42% (Evans, 2011)
Timing of spread Metastasis often appears 5-15 years or more after diagnosis
After complete removal Better local control, though long-term surveillance is still needed

The Evans series included many people treated before modern sarcoma surgery, so these figures may overestimate the risk for people treated today. Still, they show why LGFMS should never be regarded as a benign tumour.

Even when the tumour spreads to the lungs, it usually grows slowly, and many people live for years with treatment.

Why can it come back so late?

LGFMS cells divide very slowly. Small groups of cells left behind at the operation site, or that have already travelled to the lungs, can take many years to grow large enough to be noticed. This slow growth is also why chemotherapy, which works best on fast-dividing cells, is usually not very effective.

8. Follow-up

Follow-up Purpose
Clinical examination Checks the operation site for new lumps
MRI of the original site Detects local recurrence
Chest CT or X-ray Detects lung metastases
Physiotherapy reviews Supports recovery of strength and movement

Follow-up is usually every 3-6 months for the first few years and then less often, but it should continue for at least 10 years, and many experts recommend lifelong checks because of late spread.

9. Living with LGFMS

  • Keep attending follow-up, even many years after treatment
  • Report new lumps at or near the scar
  • Report persistent cough or breathlessness
  • Do your physiotherapy exercises to regain strength and movement
  • Ask about lymphoedema care if your limb swells after radiotherapy
  • Contact a sarcoma charity for information and peer support

10. Frequently asked questions

Question Answer
Is LGFMS cancer? Yes. It is a low-grade sarcoma, a type of cancer
Why was I told it looked benign? The cells look bland; expert review and MUC4 testing are needed
Can it spread? Yes, mainly to the lungs, often years later
Do I need chemotherapy? Usually not; surgery is the main treatment
How long will I need check-ups? At least 10 years, and often lifelong
Is it inherited? No. The gene change is only in the tumour
Can I exercise after treatment? Yes. Exercise and physiotherapy help recovery; your team will advise when to start
Will the scar area always feel different? Some firmness, numbness or tightness is common and often improves over months
Can children get it? Yes, though it is more common in adults

11. Questions to ask your care team

  • Was the tumour removed with clear margins?
  • Do I need radiotherapy?
  • Has the diagnosis been confirmed with MUC4 or genetic testing?
  • How often will I need scans, and for how long?
  • What should I do if I notice a new lump?
  • Are there clinical trials if the tumour comes back?

Resources

  1. Doyle, L.A. et al. (2011) ‘MUC4 is a highly sensitive and specific marker for low-grade fibromyxoid sarcoma’, American Journal of Surgical Pathology, 35(5), pp. 733-741.
  2. Evans, H.L. (2011) ‘Low-grade fibromyxoid sarcoma: a clinicopathologic study of 33 cases with long-term follow-up’, American Journal of Surgical Pathology, 35(10), pp. 1450-1462.
  3. Folpe, A.L. et al. (2000) ‘Low-grade fibromyxoid sarcoma and hyalinizing spindle cell tumor with giant rosettes: a clinicopathologic study of 73 cases supporting their identity and assessing the impact of high-grade areas’, American Journal of Surgical Pathology, 24(10), pp. 1353-1360.
  4. Gronchi, A. et al. (2021) ‘Soft tissue and visceral sarcomas: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up’, Annals of Oncology, 32(11), pp. 1348-1365.
  5. Lane, K.L., Shannon, R.J. and Weiss, S.W. (1997) ‘Hyalinizing spindle cell tumor with giant rosettes: a distinctive tumor closely resembling low-grade fibromyxoid sarcoma’, American Journal of Surgical Pathology, 21(12), pp. 1481-1488.
  6. Maretty-Nielsen, K. et al. (2013) ‘Low-grade fibromyxoid sarcoma: incidence, treatment strategy of metastases, and clinical significance of the FUS gene’, Sarcoma, 2013, 256280.
  7. Mohamed, M., Fisher, C. and Thway, K. (2017) ‘Low-grade fibromyxoid sarcoma: clinical, morphologic and genetic features’, Annals of Diagnostic Pathology, 28, pp. 60-67.
  8. Panagopoulos, I. et al. (2004) ‘The chimeric FUS/CREB3l2 gene is specific for low-grade fibromyxoid sarcoma’, Genes, Chromosomes and Cancer, 40(3), pp. 218-228.
  9. National Cancer Institute (2026) Soft Tissue Sarcoma Treatment (PDQ) – Health Professional Version. Available at: https://www.cancer.gov/types/soft-tissue-sarcoma/hp/adult-soft-tissue-treatment-pdq (Accessed: October 2026).

Prepared by the editorial team, October 2026.